BR0313423A - Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependência - Google Patents
Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependênciaInfo
- Publication number
- BR0313423A BR0313423A BR0313423-7A BR0313423A BR0313423A BR 0313423 A BR0313423 A BR 0313423A BR 0313423 A BR0313423 A BR 0313423A BR 0313423 A BR0313423 A BR 0313423A
- Authority
- BR
- Brazil
- Prior art keywords
- craving
- administration
- substance
- treatment against
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MEDICAMENTO PARA O TRATAMENTO CONTRA A âNSIA, POR UMA SUBSTâNCIA DEVIDO A UMA DEPENDêNCIA". A presente invenção refere-se a um medicamento para o tratamento contra a ânsia por algo devido a uma dependência o qual é caracterizado pelo fato que o medicamento consiste de uma combinação de duas formas de ministração, uma das formas de ministração liberando continuamente pelo menos um modulador de receptores nicotínicos e a outra forma de ministração permitindo a rápida penetração de galantamina no sistema nervoso central, assim como um método de dois estágios para a terapia contra a ânsia por uma substância através da modulação de receptores de neurónios nicotínicos, no qual um tratamento permanente com uma forma de ministração farmacêutica a qual libera continuamente um modulador de receptores nicotínicos é suplementado quando do surgimento de uma forte ânsia por uma substância pela ministração de galantamina ou de um sal farmacologicamente aceitável proveniente do mesmo por meio de uma forma de ministração a qual permite uma rápida penetração deste modulador no sistema nervoso central.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10235556A DE10235556A1 (de) | 2002-08-03 | 2002-08-03 | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| PCT/EP2003/008236 WO2004014393A1 (de) | 2002-08-03 | 2003-07-25 | Medikament und verfahren zur verringerung des alkohol-und/oder tabakkonsums |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313423A true BR0313423A (pt) | 2005-06-28 |
Family
ID=30469388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313423-7A BR0313423A (pt) | 2002-08-03 | 2003-07-25 | Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependência |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060079500A1 (pt) |
| EP (1) | EP1524982B1 (pt) |
| JP (1) | JP2006501212A (pt) |
| KR (1) | KR100736016B1 (pt) |
| CN (1) | CN1674911A (pt) |
| AR (1) | AR040762A1 (pt) |
| AT (1) | ATE458488T1 (pt) |
| AU (1) | AU2003253327B2 (pt) |
| BR (1) | BR0313423A (pt) |
| CA (1) | CA2495418A1 (pt) |
| DE (2) | DE10235556A1 (pt) |
| EA (1) | EA012460B1 (pt) |
| IL (1) | IL166464A0 (pt) |
| MX (1) | MXPA05001294A (pt) |
| MY (1) | MY142346A (pt) |
| NO (1) | NO20050376L (pt) |
| PL (1) | PL375404A1 (pt) |
| TW (1) | TW200402297A (pt) |
| UA (1) | UA84405C2 (pt) |
| WO (1) | WO2004014393A1 (pt) |
| ZA (1) | ZA200500510B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2906265A (en) * | 1957-09-03 | 1959-09-29 | Maryland Devices Inc | Nasal adaptor for valved dispenser |
| US4597961A (en) * | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5336675A (en) | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| DE69912311T2 (de) * | 1998-12-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Galantamin-zusammensetzung mit gesteuerter freisetzung |
| US6369058B1 (en) * | 1999-02-04 | 2002-04-09 | New Millennium Pharmaceutical Research Inc. | Brain delivery of folic acid for the prevention of alzheimer's disease and stroke |
| US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| EP1423127A1 (en) * | 2001-08-30 | 2004-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
-
2002
- 2002-08-03 DE DE10235556A patent/DE10235556A1/de not_active Withdrawn
-
2003
- 2003-07-25 CN CNA038186381A patent/CN1674911A/zh active Pending
- 2003-07-25 MX MXPA05001294A patent/MXPA05001294A/es active IP Right Grant
- 2003-07-25 PL PL03375404A patent/PL375404A1/xx not_active Application Discontinuation
- 2003-07-25 BR BR0313423-7A patent/BR0313423A/pt not_active IP Right Cessation
- 2003-07-25 UA UAA200500950A patent/UA84405C2/ru unknown
- 2003-07-25 DE DE50312449T patent/DE50312449D1/de not_active Expired - Fee Related
- 2003-07-25 US US10/523,012 patent/US20060079500A1/en not_active Abandoned
- 2003-07-25 AT AT03784081T patent/ATE458488T1/de not_active IP Right Cessation
- 2003-07-25 KR KR1020057001996A patent/KR100736016B1/ko not_active IP Right Cessation
- 2003-07-25 EA EA200500140A patent/EA012460B1/ru not_active IP Right Cessation
- 2003-07-25 EP EP03784081A patent/EP1524982B1/de not_active Expired - Lifetime
- 2003-07-25 CA CA002495418A patent/CA2495418A1/en not_active Abandoned
- 2003-07-25 JP JP2004526790A patent/JP2006501212A/ja active Pending
- 2003-07-25 WO PCT/EP2003/008236 patent/WO2004014393A1/de active Application Filing
- 2003-07-25 AU AU2003253327A patent/AU2003253327B2/en not_active Ceased
- 2003-08-01 MY MYPI20032921A patent/MY142346A/en unknown
- 2003-08-01 AR AR20030102773A patent/AR040762A1/es unknown
- 2003-08-01 TW TW092121119A patent/TW200402297A/zh unknown
-
2005
- 2005-01-19 ZA ZA200500510A patent/ZA200500510B/en unknown
- 2005-01-24 IL IL16646405A patent/IL166464A0/xx unknown
- 2005-01-24 NO NO20050376A patent/NO20050376L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE458488T1 (de) | 2010-03-15 |
| TW200402297A (en) | 2004-02-16 |
| IL166464A0 (en) | 2006-01-15 |
| EA200500140A1 (ru) | 2005-06-30 |
| EP1524982B1 (de) | 2010-02-24 |
| AU2003253327A1 (en) | 2004-02-25 |
| WO2004014393A1 (de) | 2004-02-19 |
| DE50312449D1 (de) | 2010-04-08 |
| JP2006501212A (ja) | 2006-01-12 |
| AU2003253327B2 (en) | 2009-10-08 |
| DE10235556A1 (de) | 2004-02-19 |
| US20060079500A1 (en) | 2006-04-13 |
| MY142346A (en) | 2010-11-15 |
| PL375404A1 (en) | 2005-11-28 |
| UA84405C2 (ru) | 2008-10-27 |
| KR100736016B1 (ko) | 2007-07-06 |
| NO20050376L (no) | 2005-01-24 |
| EA012460B1 (ru) | 2009-10-30 |
| KR20050032590A (ko) | 2005-04-07 |
| ZA200500510B (en) | 2005-07-19 |
| AR040762A1 (es) | 2005-04-20 |
| CA2495418A1 (en) | 2004-02-19 |
| MXPA05001294A (es) | 2005-09-08 |
| CN1674911A (zh) | 2005-09-28 |
| EP1524982A1 (de) | 2005-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308482A (pt) | Sistema de administração de droga implantável | |
| BR112018016420A2 (pt) | produtos de combinação opioide e dispositivo com perfis de segurança e eficácia aperfeiçoados | |
| BRPI0415858A (pt) | compostos de medicamentos terapêuticos modificados por tocoferol | |
| EP1611880A3 (en) | Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction | |
| BR0115392A (pt) | Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga | |
| NO20055880L (no) | Memantin orale doseringsformer | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| BRPI0518093A (pt) | dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro | |
| WO2006015299A3 (en) | Multi-reservoir device for transdermal drug delivery and sensing | |
| MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
| MX2009010000A (es) | Dispositivo para el suministro de farmaco. | |
| CA2601715A1 (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
| GB2435211B (en) | Drug delivery system | |
| PE20110711A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma | |
| Ono et al. | Chewing Prevents Stress‐Induced Hippocampal LTD Formation and Anxiety‐Related Behaviors: A Possible Role of the Dopaminergic System | |
| WO2008025790A3 (en) | Use of opioid formulations in needle-less drug delivery devices | |
| Feng et al. | Effects of central activation of serotonin 5-HT 2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test | |
| Sasaki-Hamada et al. | Riluzole does not affect hippocampal synaptic plasticity and spatial memory, which are impaired by diazepam in rats | |
| BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts | |
| BR0313423A (pt) | Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependência | |
| Shader | Sexual dysfunction associated with mesoridazine besylate (Serentil) | |
| Shimizu et al. | Delayed L-DOPA-induced hyperalgesia | |
| Serra et al. | Effects of sufentanil on the release and metabolism of dopamine and ascorbic acid and glutamate release in the striatum of freely moving rats | |
| Rustamovich et al. | RATIONAL USE OF NARCOTIC ANALGESICS, ANESTHETICS AND LOCAL ANESTHETICS IN PAIN SYNDROME. | |
| Healey | An Examination of D-Serine Augmentation on the Behavioral and Cellular Mechanisms of Cocaine Seeking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/5513, 31/465; A61P 25/30, 25/32, 25/34 Ipc: A61K 31/5513 (2011.01), A61K 31/465 (2011.01), A61 |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |